Genex, $13 Million Technology Transfer for Anemia Treatment
[Asia Economy Reporter Ji Yeon-jin] Genexine announced on the 24th that it has licensed the technology of the sustained-release anemia treatment drug (GX-E4) to Indonesian pharmaceutical company KGBIO for $13 million (15.8 billion KRW).
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Electronics Union: "Mediation Ends Due to Management's Rejection... General Strike Tomorrow"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The signing fee is $8 million (9.7 billion KRW), and $5 million (6.1 billion KRW) will be received as milestones.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
